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Abstract: Ocular metastasis from lung cancer is uncommon. We
report a patient with metastatic non-small cell lung cancer who was
found to have a metastatic lesion in the choroid at the time of
presentation. The patient was treated with carboplatin, gemcitabine,
and bevacizumab. After three cycles of chemotherapy, radiologic
imaging and ophthalmologic examination demonstrated complete
resolution of the choroid lesion. This case report demonstrates the
durable response of choroidal metastasis from non-small cell lung
cancer to systemic bevacizumab and chemotherapy.
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(J Thorac Oncol. 2009;4: 661–662)
A 42-year-old woman with newly diagnosed metastaticnon-small cell lung cancer (poorly differentiated large
cell carcinoma) presented with 1 week history of blurred
vision in her right eye and metamorphopsia where flat sur-
faces appeared curved. A computerized tomography scan of
the neck and chest performed at initial presentation had
revealed multiple left pulmonary masses, a right upper lobe
lesion as well as enlarged left anterior cervical, bilateral
supraclavicular, mediastinal, prevascular, paratracheal, and
subcarinal lymph nodes. Pathologic diagnosis of poorly dif-
ferentiated large cell carcinoma was obtained from core-
needle biopsy of the left anterior cervical lymph node. Brain
magnetic resonance imaging revealed a metastatic lesion in
the choroid of the right globe (Figure 1A). Ophthalmology
evaluation of the right fundus showed a 12  12 mm
amelanotic choroidal tumor at the fovea and temporal macula
with overlying subretinal fluid and an associated inferior
exudative retinal detachment (Figure 1B). Tumor height was
6.3 mm with high internal reflectivity on ocular echography.
Systemic chemotherapy was initiated. After her first cycle
of carboplatin, gemcitabine, and bevacizumab, she experienced
improvement in visual symptoms. Magnetic resonance imaging
after cycle 3 of chemotherapy showed complete resolution of the
choroid lesion (Figure 2A), coinciding with improvement in her
vision (Figure 2B) and disease response systemically. Subse-
quently, she completed six cycles of chemotherapy and attained
a partial response in her lung mass. At the time of this report she
was alive with normal vision and receiving her seventh mainte-
nance dose of every 3 week bevacizumab without experiencing
systemic or ocular toxicity.
DISCUSSION
The highly vascular uveal tract is the most common part
of the eye involved by metastases.1 Within the uvea, the choroid
(88%) is the most commonly affected site followed by the iris
(9%) and ciliary body (2%).2 Breast and lung cancers are the
predominant tumors to metastasize to the uvea,2,3 and between
67 and 88% of patients have metastatic lesions elsewhere at the
time of diagnosis of ocular involvement.4
Although fine-needle aspiration biopsy can be used to
establish the diagnosis; the choroidal tumor characteristics, pres-
ence of distant metastases, and patient history were sufficient to
infer the diagnosis of choroidal metastasis in this case.
Treatment for orbital and ocular adnexal metastases is
palliative because the presence of such metastases suggests
hematogenous spread of cancer. In line with this, the aims for
treatment are to maximize quality of life, and restore or
preserve vision. This may be achieved with either radiother-
apy or chemotherapy. Surgery has not played an important
role (other than diagnostic biopsy, if needed) as surgery
carries great potential morbidity and often there is no need for
tumor debulking.
External beam radiotherapy in the range of 20 to 50 Gy
has been commonly used5 and achieves symptom relief al-
though controlling tumor growth. This modality is particu-
larly applicable for large tumors that involve the optic nerve/
macula and cause substantial visual disturbance. Visual
preservation after external beam radiotherapy may be only for
the short-term because potential long-term side effects in-
clude cataract formation and radiation retinopathy.5 Radioac-
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tive plaque therapy may be used for single small to medium-
sized tumors.6
Systemic chemotherapy is effective in treating ocular
metastases especially in chemosensitive tumors such as small
cell lung cancer. Several case reports have shown that che-
motherapy is efficacious for choroid metastases from non-
small cell lung cancer.7,8 In our case, standard platinum
doublet chemotherapy was used as the initial and primary
treatment because the patient has other concurrent sites of
metastatic disease which require simultaneous attention.
Intravitreal bevacizumab monotherapy has been used to
treat choroid metastases.9,10 Both reports demonstrated anti-
angiogenic and antipermeability effects of bevacizumab on
the new tumor vessels by fluorescein angiography. These
observations suggest the obligate and vital dependence of
choroidal tumors on angiogenesis. This forms the rationale
for the use of systemic bevacizumab in our patient, apart
from the fact that a platinum doublet in combination with
bevacizumab is standard therapy in the United States.
Furthermore, systemic administration of bevacizumab was
chosen over intravitreal injections due to its greater poten-
tial to produce effective chemotherapy concentrations
around the metastasis via the rich choroidal blood supply
which is within the systemic circulation and not protected
by the blood-retina barrier.
To our knowledge this is the first case demonstrating
that the efficacy and safety of systemic bevacizumab in
combination with a platinum doublet for choroid metastasis
resulting in symptomatic improvement and durable control of
the tumor with minimal ocular or systemic toxicity.
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FIGURE 1. A, Magnetic resonance imaging
(MRI) brain at presentation revealing a meta-
static lesion in the choroid of the right globe
(white block arrow). B, Ophthalmology evalua-
tion of the right fundus showing a 12  12
mm amelanotic choroidal tumor at the fovea
and temporal macula (black block arrow) with
overlying subretinal fluid and an associated in-
ferior exudative retinal detachment (black line
arrow).
FIGURE 2. A, Magnetic resonance imaging
(MRI) brain after three cycles of chemotherapy
showing complete resolution of the choroid
lesion. B, Ophthalmology images postchemo-
therapy showing complete resolution of the
choroid lesion.
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